News Morepen Laboratories Limited

Stocks

500288

INE083A01026

Pharmaceuticals

Market Closed - Bombay S.E. 06:20:14 2026-10-28 EDT			5-day change	1st Jan Change
125.90 ^INR	-4.98%		+8.72%	+206.55%

10-27	Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
09-28	Morepen Laboratories Limited Submits First U.S. ANDA For Sitagliptin Tablets USP	CI

All News

Mentions Relevance

10-27	Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
09-28	Morepen Laboratories Limited Submits First U.S. ANDA For Sitagliptin Tablets USP	CI
09-26	Morepen Laboratories Limited Approves Change in Designation of Mr. Sanjay Suri from Whole-Time Director to Managing Director	CI
08-17	Morepen Laboratories : Annual Report 2025-26	PU
08-05	Morepen Laboratories Limited announces Annual dividend, payable on October 26, 2026	CI
08-04	Morepen Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-04	Morepen Laboratories : Q1'FY27 Investor Presentations	PU
06-30	Morepen Laboratories Limited Accelerates Manufacturing Expansion, Plans 1,000 KL Reactor Capacity	CI
06-30	Morepen Scales Up CDMO Program, Expects INR 2.25 Billion Supplies in Second Quarter of 2027	CI
05-26	Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-26	Morepen Laboratories : Audited Financial results for the quarter and financial year ended March 31, 2026 Unaudited financial results for the quarter and nine months ended December 31, 2025 Unaudited Financial results for the quarter and half year ended September 30, 2025 Unaudited Financial results for the quarter ended June 30, 2025	PU
05-26	Morepen Laboratories Limited Recommends Final Dividend for the Year Ended 31 March, 2026	CI
05-26	Morepen Laboratories March-quarter consol net profit 157 million rupees	RE
05-19	Anubhav Suri agreed to acquire an additional 9% stake in Morepen Medipath Limited from Morepen Laboratories Limited.	CI
04-23	Morepen Laboratories Limited Approves Unsecured Term Loan Facility of INR 300 Million from Shinhan Bank	CI
04-17	Morepen Laboratories : Secures Fourth Consecutive USFDA Inspection with Zero Observations (NIL 483)	PU
04-17	Morepen Laboratories says USFDA clears Masulkhana API facility with nil Form 483 observations	RE
04-17	Morepen Laboratories Limited Receives USFDA Clearance for Masulkhana Facility Inspection with Zero Observations	CI
02-23	Morepen Laboratories gets order worth 8.25 bln rupees	RE
02-23	Morepen Laboratories Secures INR8.25 Billion CDMO Mandate; Shares Jump 13%	MT
02-23	Morepen Laboratories : Bags ₹825 Crore Global Deal; Expands Into High-Growth CDMO Segment.	PU
02-22	Morepen Laboratories : Bags ₹825 Crore Global Deal	PU
02-22	Morepen Laboratories secures 8.25 billion rupees CDMO deal	RE
02-22	Morepen Laboratories Limited Secures Multi-Year Contract Development and Manufacturing Organization	CI
02-12	Morepen Laboratories Limited Executes Loan Agreement and Other Related Documents with Woori Bank	CI